More importantly, the effect of the KDM7A inhibitor TC-E 5002 on prostate cancer cell proliferation was analyzed, and we observed that prostate cancer cell growth was reduced on treatment with TC-E 5002 treatment. Here, KDM7A is linked to prostate carcinoma.